Accès ouvert
2025
article
OpenAlex
Cristina de Mello-Sampayo, Mafalda Soares Pádua, Mario Silva, Maria Eduarda Marques Lourenço et autres
Alzheimer’s disease (AD) is the most common form of dementia, affecting over 50 million people globally. Since 1906, efforts to understand this neurodegenerative disease and to develop effective treatments have continued to this day. Recognizing docosahexaenoic acid (DHA, 22:6n-3) as a safe, …
pt
(code pays fourni par la source)
Accès ouvert
2025
article
OpenAlex
Paula A. Lopes, Mafalda Soares Pádua, José Luis Guil‐Guerrero
Alzheimer’s disease (AD) is the most common cause of dementia, and no cure is currently available. The β-amyloid cascade of AD and neurofibrillary tangles are the basis of the current understanding of AD pathogenesis, driving drug investigation and other discoveries. Up until …
pt, es
(code pays fourni par la source)
Accès ouvert
2024
article
OpenAlex
Mafalda Soares Pádua, José Luis Guil‐Guerrero, Paula A. Lopes
The 5xFAD transgenic mouse model widely used in Alzheimer's disease (AD) research recapitulates many AD-related phenotypes with a relatively early onset and aggressive age-dependent progression. Besides developing amyloid peptide deposits alongside neuroinflammation by the age of 2 months, as well as exhibiting …
pt, es
(code pays fourni par la source)
Accès ouvert
2024
article
OpenAlex
Mafalda Soares Pádua, José Luis Guil‐Guerrero, José A. M. Prates, Paula A. Lopes
Alzheimer's disease (AD), the leading cause of dementia, presents a significant global health challenge with no known cure to date. Central to our understanding of AD pathogenesis is the β-amyloid cascade hypothesis, which underlies drug research and discovery efforts. Despite extensive studies, …
pt, es
(code pays fourni par la source)